Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation
Source: Streetwise Reports  (9/20/19)
Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Products for Human Use also adopted a positive opinion for Dupixent in a third indication. More >

Biopharma Reports Positive Data from Alcoholic Hepatitis Study
Source: Streetwise Reports  (9/18/19)
These results are from the recently completed clinical trial of the firm's lead drug candidate. More >

NCI Chooses Veterinary Biopharma as Select Manufacturing Contractor
Source: Streetwise Reports  (9/18/19)
The contract's meaning, terms and benefits and the California firm's near-term catalysts are discussed in an H.C. Wainwright & Co. report. More >

Alder BioPharmaceuticals Shares Surge 80% on Acquisition News
Source: Streetwise Reports  (9/16/19)
Shares of migraine treatment research firm Alder BioPharmaceuticals opened 84% higher today after the company announced that it has agreed to be acquired by H. Lundbeck for $1.95 billion. More >

Fibrocell Science Shares Rise 60% on Acquisition News
Source: Streetwise Reports  (9/13/19)
Fibrocell Science's shares are trading up 60% today after the company announced that it agreed to be acquired by Castle Creek Holdings for $63.3 million, or $3.00 per share. More >

Moderna Shares Rise on the Release of Positive Results from Two mRNA Phase 1 Programs
Source: Streetwise Reports  (9/12/19)
Shares of Moderna Inc. traded up double-digits as the firm announced results from its Phase 1 CMV Vaccine Study as well as its Phase 1 data for mRNA-1944 encoding for antibody against the chikungunya virus. More >

Company Develops Cannabinoid-Measuring Process for Liquids
Source: Streetwise Reports  (9/11/19)
This proprietary method ensures the firm meets the requirements for its cannabis-containing beverages and oils. More >

Sanofi Pays Lexicon Pharma $260 Million to Settle Diabetes Drug Dispute
Source: Streetwise Reports  (9/11/19)
Lexicon Pharmaceuticals shares traded higher by more than 30% today after the company announced termination of its alliance with Sanofi SA and a $260 million settlement over its diabetes drug Zynquista. More >

Biopharma Makes Licensing Deal for Therapeutic Rights in Japan
Source: Streetwise Reports  (9/11/19)
The company's reasons for the transaction and expected short-term, stock-moving events are provided in a ROTH Capital Partners report. More >

T2 Biosystems Receives BARDA Contract to Fight Antimicrobial Resistance, Shares Up More than 88%
Source: Streetwise Reports  (9/11/19)
This healthcare diagnostics stock rose more than 88% on Wednesday following the award of a BARDA contract that could be worth up to $69 million. More >

Mallinckrodt Shares Up 60% as It Announces Sale of Unit
Source: Streetwise Reports  (9/10/19)
Shares of Mallinckrodt Plc are trading more than 60% higher today on news that the company is selling its CDMO subsidiary BioVectra Inc. to H.I.G. Capital for $250 million. More >

ACADIA Pharma's Shares Open 75% Higher on Positive Anti-Psychosis Drug Phase 3 Results
Source: Streetwise Reports  (9/9/19)
Shares of ACADIA Pharmaceuticals opened up 75% higher today after the company announced that its Phase 3 Study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoint. More >

Technology License Triggers $10 Million Milestone Payment for Biopharma
Source: Streetwise Reports  (9/9/19)
This is the first of many such potential payments under the related agreement. More >

Neon Therapeutics Shares Are Flashing Brightly after Reporting Predictive Cancer Breakthrough
Source: Streetwise Reports  (9/6/19)
After announcing publication in the scientific journal Immunity that it had created a 61-fold improvement process for predicting cancer-specific antigens, Neon Therapeutics' stock has traded wildly today, up more than 46% at times on nearly 100-times average daily volume, but has since pulled back greatly. More >

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%
Source: Streetwise Reports  (9/5/19)
Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. More >

Coverage Initiated on 'Biotech Machine'
Source: Streetwise Reports  (9/4/19)
The compelling reasons behind those descriptors are explored in a Dawson James Securities report. More >

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'
Source: Streetwise Reports  (9/4/19)
The study data and their implications are provided in a BTIG report. More >

Fiscal Year 'Reads Well' for Regenerative Medicine Company
Source: Streetwise Reports  (9/4/19)
The firm's final quarter and full-year results are reviewed in a Ladenburg Thalmann report. More >

Ardelyx's Shares Soar 65% as Tenapanor Phase 3 Study Hits the Mark
Source: Streetwise Reports  (9/3/19)
Clinical-stage specialized biopharmaceutical company Ardelyx announced positive results today for its phase 3 AMPLIFY study for tenapanor aimed at improving treatment for cardiorenal diseases. More >

Lannett Signs Exclusive U.S. Distribution Deal with Sinotherapeutics; Shares Up 40%
Source: Streetwise Reports  (8/28/19)
Shares of Lannett Co. are up 40% today after announcing that it secured rights to be the exclusive U.S. distributor of Sinotherapeutics' antifungal drug that is an AB-rated generic for Noxafil. More >

FDA Approves First-of-Its-Kind, Adult Pneumonia Antibiotic; September Launch Planned
Source: Streetwise Reports  (8/27/19)
The drug's features and its developer's commercial plans are discussed in an H.C. Wainwright & Co. report. More >

After Biotech Dives Deeper Into Melanoma Data, It 'Continues to Impress'
Source: Streetwise Reports  (8/27/19)
Details from this clinical program are discussed, along with Q2/19 earnings and the next stock catalyst, in an H.C. Wainwright & Co. report. More >

Developer of Premix for Livestock Feed Lands Sizable Order from Asia
Source: Streetwise Reports  (8/26/19)
Demand for the Canadian company's product is growing in the Asia-Pacific region. More >

Why Provention Bio Is in My Portfolio
Source: Daniel Carlson for Streetwise Reports  (8/23/19)
Orphan drug and breakthrough therapy status, which could mean this company's lead candidate is on the FDA fast track, translates to huge opportunities for both those suffering from diabetes and investors, says Daniel Carlson of Tailwinds Research. More >

Retrophin Shares Fall 30% on Failed Phase 3 FORT Study
Source: Streetwise Reports  (8/22/19)
Shares of Retrophin fell to a 52-week low on the news that topline results from its fosmetpantotenate Phase 3 FORT Study for PKNA treatment failed to meet expectations. More >